dc.contributor.author
Kupitz, Dennis
dc.contributor.author
Wetz, Christoph
dc.contributor.author
Wissel, Heiko
dc.contributor.author
Wedel, Florian
dc.contributor.author
Apostolova, Ivayla
dc.contributor.author
Wallbaum, Thekla
dc.contributor.author
Rieke, Jens
dc.contributor.author
Amthauer, Holger
dc.contributor.author
Grosser, Oliver S.
dc.date.accessioned
2018-06-08T10:45:04Z
dc.date.available
2017-12-22T11:32:59.954Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/21006
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-24303
dc.description.abstract
In peptide receptor radionuclide therapy (PRRT) of patients with
neuroendocrine neoplasias (NENs), intratherapeutic dosimetry is mandatory for
organs at risk (e.g. kidneys) and tumours. We evaluated commercial dosimetry
software (Dosimetry Toolkit) using varying imaging scenarios, based on planar
and/or tomographic data, regarding the differences in calculated organ/tumour
doses and the use for clinical routines. A total of 16 consecutive patients
with NENs treated by PRRT with 177Lu-DOTATATE were retrospectively analysed.
Single-photon emission computed tomography (SPECT)/low-dose computed
tomography (CT) of the thorax and abdomen and whole body (WB) scintigraphy
were acquired up to 7 days p.i. (at a maximum of five imaging time points).
Different dosimetric scenarios were evaluated: (1) a multi-SPECT-CT scenario
using SPECT/CT only; (2) a planar scenario using WB scintigraphy only; and (3)
a hybrid scenario using WB scintigraphy in combination with a single SPECT
/low-dose CT. Absorbed doses for the kidneys, liver, spleen, lungs, bladder
wall and tumours were calculated and compared for the three different
scenarios. The mean absorbed dose for the kidneys estimated by the multi-
SPECT-CT, the planar and the hybrid scenario was 0.5 ± 0.2 Sv GBq-1, 0.8 ± 0.4
Sv GBq-1 and 0.6 ± 0.3 Sv GBq-1, respectively. The absorbed dose for the
residual organs was estimated higher by the planar scenario compared to the
multi-SPECT-CT or hybrid scenario. The mean absorbed tumour doses were 2.6 ±
1.5 Gy GBq-1 for the multi-SPECT-CT, 3.1 ± 2.2 Gy GBq-1 for the hybrid
scenario and 5.3 ± 6.3 Gy GBq-1 for the planar scenario. SPECT-based dosimetry
methods determined significantly lower kidney doses than the WB scintigraphy-
based method. Dosimetry based completely on SPECT data is time-consuming and
tedious. Approaches combining SPECT/CT and WB scintigraphy have the potential
to ensure compromise between accuracy and user-friendliness.
de
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
Software-assisted dosimetry in peptide receptor radionuclide therapy with
177Lutetium-DOTATATE for various imaging scenarios
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
PLoS ONE. - 12 (2017), 11, Artikel Nr. e0187570
dcterms.bibliographicCitation.doi
10.1371/journal.pone.0187570
dcterms.bibliographicCitation.url
http://doi.org/10.1371/journal.pone.0187570
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000028704
refubium.note.author
Der Artikel wurde in einer reinen Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000009280
dcterms.accessRights.openaire
open access